Detalles de la búsqueda
1.
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
Haematologica
; 108(1): 110-121, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35770532
2.
Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study.
Biol Blood Marrow Transplant
; 24(11): 2265-2270, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30031070
3.
T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Am J Hematol
; 93(6): 736-744, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29498106
4.
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Lancet Oncol
; 17(8): 1127-1136, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-27402145
5.
Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant
; 20(1): 66-72, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24141006
6.
Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study.
J Immunother Cancer
; 12(1)2024 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38199608
7.
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Bone Marrow Transplant
; 59(3): 395-402, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38195984
8.
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT.
J Hematol Oncol
; 16(1): 58, 2023 05 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37248463
9.
Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party.
J Immunother Cancer
; 11(4)2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37072350
10.
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Bone Marrow Transplant
; 58(6): 673-679, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36918682
11.
Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT.
Bone Marrow Transplant
; 57(4): 562-571, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35079140
12.
Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT.
J Hematol Oncol
; 16(1): 106, 2023 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37775766
13.
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Bone Marrow Transplant
; 58(6): 738, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37076611
Resultados
1 -
13
de 13
1
Próxima >
>>